Tag Archives: American Society of Clinical Oncology

IPO breakout starts summer off with a bang; but two new issues fizzle.

It was certainly an off week (June 26 to 30, 2017) to for healthcare stocks, with the Nasdaq Healthcare Index (IXHC) giving back 2% to 732.05 after hitting an all-time… Read more »

ASCO, aka The Oncology Super Bowl for Biotechs, sends stocks in every direction

Steve’s Take: As another jam-packed annual meeting of the American Society of Clinical Oncology in Chicago wrapped up on Tuesday (June 6, 2017), with some 38,000 oncologists gathering together at… Read more »

Tesaro says it’s for sale, but who can afford it

The News: Just ahead of the year’s biggest download of cancer data, the maker of a closely watched drug has put itself up for sale, according to The Wall Street… Read more »

What’s wrong with Novartis? Actually nothing.

The News: Novartis AG (Basel CHE) has been the subject of widespread and lingering chatter to the effect that its stature among the Big Pharma league players has diminished, and… Read more »

Week’s opening stock roundup: gainers include Novocure, Steadymed; but Corvus, NewLink rocked

Here to start your trading week are the major movers from last week and where they stand this morning: Novocure (Nasdaq: NVCR) led advancing issues, soaring $3.25, or 40% over the… Read more »

Study Says Gene Test Spots Cancer Patients Who Could Avoid Chemo

For patients facing a diagnosis of early stage breast cancer, the traditional course of treatment is typically surgery, followed by an often difficult course of chemotherapy to try to make… Read more »

AbbVie Agrees to Buy Stemcentrx, Reports Jump in Earnings

U.S. biopharmaceutical firm AbbVie Inc. (North Chicago) on Thursday said it will acquire cancer biotech company Stemcentrx Inc. (South San Francisco) in a roughly $5.8 billion cash and stock deal that would expand… Read more »